BMS agrees to acquire Karuna Therapeutics for $14bn
Pharmaceutical Technology
DECEMBER 26, 2023
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of Karuna Therapeutics for $14bn in cash.
Tue.Dec 26, 2023
243 
KarXT: A New Hope for Schizophrenia Patients, Phase III Trial Data Reveals
XTalks
DECEMBER 26, 2023
Karuna Therapeutics, a biopharmaceutical company dedicated to uncovering, advancing and providing groundbreaking medicines for individuals facing psychiatric and neurological conditions, has recently disclosed encouraging outcomes from the Phase III EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults diagnosed with schizophrenia. “New treatments and novel mechanisms are urgently needed for people with schizophrenia because many don’t respond to their therapy and others only have a partial
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ABBV-400 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Investing in healthspan: A prescription for prosperity
pharmaphorum
DECEMBER 26, 2023
Exploring the powerful collaborations between scientists, investors, and the medical community in finding breakthrough treatments for major diseases, and the notion of 'healthspan'
Exarafenib by Kinnate Biopharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
Exarafenib is under clinical development by Kinnate Biopharma and currently in Phase I for Non-Small Cell Lung Cancer.
Exploring the reasons behind increasing burdens on clinical research sites
pharmaphorum
DECEMBER 26, 2023
In the first of a five-part festive instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Advarra’s chief product officer, Elisa Cascade, about the reasons behind increasing burdens on clinical research sites over the last five years.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
New patent for Purdue Pharma drug HYSINGLA ER
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
Difficult biotech investment ecosystem forces focus on value
Pharmaceutical Technology
DECEMBER 26, 2023
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
New patent for Blueprint Medicines drug AYVAKIT
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents… The post New patent for Blueprint Medicines drug AYVAKIT appeared first on DrugPatentWatch - Make Better Decisions.
NVG-111 by NovalGen for Mantle Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
New patent expiration for Woodward drug COREG CR
Drug Patent Watch
DECEMBER 26, 2023
Annual Drug Patent Expirations for COREG+CR Coreg Cr is a drug marketed by Woodward and is included in one NDA. It is available from four suppliers. There are two patents… The post New patent expiration for Woodward drug COREG CR appeared first on DrugPatentWatch - Make Better Decisions.
AWT-020 by Anwita Biosciences for Sarcomas: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Sarcomas.
Key industry partnerships advancing drug discovery
Drug Discovery World
DECEMBER 26, 2023
Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe. Donidalorsen is an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein, or PKK, pathway.
Sacituzumab tirumotecan by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
AZ makes another cell therapy play with $1.2bn Gracell buy
pharmaphorum
DECEMBER 26, 2023
AstraZeneca agrees a $1.
KSQ-4279 by F. Hoffmann-La Roche for Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.
Top 5 Most Popular Cold Chain Articles of 2023
Pharmaceutical Commerce
DECEMBER 26, 2023
Items in this sector ranged touched on topics such as pharma shipping, container technology, and sustainability.
BI-765179 by Boehringer Ingelheim International for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Which pharmaceutical companies have the most emulsion dosed drugs?
Drug Patent Watch
DECEMBER 26, 2023
This chart shows the pharmaceutical companies with the most emulsion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most emulsion dosed drugs… The post Which pharmaceutical companies have the most emulsion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
BI-765179 by Boehringer Ingelheim International for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC).
DDW readers’ top drug discovery developments of 2023
Drug Discovery World
DECEMBER 26, 2023
DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance and prevent the spread of disease.
BR-790 by Jiangxi Qingfeng Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
BR-790 is under clinical development by Jiangxi Qingfeng Pharmaceutical and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Roles and Responsibilities of Specialized Clinical Supply Experts
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Sacituzumab tirumotecan by Merck for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Sacituzumab tirumotecan by Merck for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
AZD-9550 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
HEC-88473 by HEC Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
HEC-88473 is under clinical development by HEC Pharma and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
TAK-500 by Takeda Pharmaceutical for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
TAK-500 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
NT-175 is under clinical development by Neogene Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Pharmaceutical Technology
DECEMBER 26, 2023
ORB-011 is under clinical development by Orionis Biosciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Accelerating Clinical Supply Through Integrated Drug Development
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Let's personalize your content